Research Library › GHRH & Ghrelin-Receptor
AOD-9604 is a synthetic 16-amino-acid peptide modeled on residues 177 to 191 at the C-terminal end of human growth hormone, with one added tyrosine. It was developed by a biochemistry group at Monash University in Australia in the late 1990s and taken into clinical development by Metabolic Pharmaceuticals. As of 22 Oct 2026 it is not approved as a medicine in any country, and an FDA advisory committee voted 12–0 in December 2024 against adding it to the 503A compounding bulks list.
Key facts
| Type | Synthetic 16-amino-acid peptide (hexadecapeptide) |
|---|---|
| Derived from | Human growth hormone, residues 177–191, plus an added tyrosine |
| First described | 2000, Monash University (Ng et al., Hormone Research) |
| Developed by | Monash University; Metabolic Pharmaceuticals (founded 1998) |
| Designed target | Lipid-metabolism signaling in adipose tissue (proposed, preclinical) |
| Regulatory status (Oct 2026) | Not FDA-approved; not approved elsewhere; PCAC voted 12–0 against 503A listing (Dec 2024); named on WADA 2026 list (S2) |
Who developed it
AOD-9604 came out of a biochemistry group at Monash University in Melbourne, Australia. The first full research paper on the compound, published in 2000, lists F.M. Ng as lead author alongside departmental colleagues [1].
In 1998 a company, Metabolic Pharmaceuticals, was formed around the Monash work. It held the program’s intellectual property and ran the compound’s human trials through the mid-2000s [2][3].
What it was designed to target
Human growth hormone is a 191-amino-acid protein with several distinct activities. Earlier research had associated a region near its C-terminal end with the hormone’s role in lipid metabolism. AOD-9604 reproduces residues 177 to 191 of that sequence and adds a tyrosine, giving a 16-residue peptide [3][4].
The design idea was to isolate that region as a stand-alone fragment that could be studied for lipid-metabolism signaling in adipose tissue, separately from the full hormone’s growth-promoting pathways. The proposed mechanism was characterized in rodent studies; FDA’s 2024 review describes the supporting data as largely preclinical [1][3].
Why it was created
AOD-9604 was originally investigated in a research program on obesity. Full-length growth hormone acts on many tissues and is known to affect blood glucose regulation, which made it a poor starting point for that program. The Monash team asked whether a small fragment could be separated from those broader actions [1].
Research timeline
- Late 1990s: Developed and patented in Australia; Metabolic Pharmaceuticals founded in 1998 [2][3].
- 2000: Monash publishes the first metabolic study of AOD-9604 in a rat model [1].
- 2004: A phase 2 trial of about 300 participants reports results that draw analyst skepticism [5].
- 2007: The larger OPTIONS trial, in 536 adults, does not meet its objectives; in February the company says it will not continue AOD-9604 as an obesity drug [3].
- 2013: A human safety and tolerability analysis is published [4].
- Nov 2024: FDA publishes its evaluation of AOD-9604 for the 503A bulks list [3].
- Dec 2024: FDA’s Pharmacy Compounding Advisory Committee votes 12–0 against listing [6].
Regulatory status as of October 2026
As of 22 Oct 2026, AOD-9604 is not FDA-approved, and no approval in any other country has been identified. FDA evaluated it as a nominated bulk drug substance for 503A pharmacy compounding, and on 4 December 2024 the Pharmacy Compounding Advisory Committee (PCAC) voted 12–0 against adding it to the bulks list [3][6]. A separate compounding nomination was later withdrawn [3].
FDA’s page on safety risks of nominated bulk substances lists possible immunogenicity and reported serious adverse events for AOD-9604, while noting that causality is not clear [7]. On 14 October 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its text and peptide list are not public [8].
AOD-9604 is named on the 2026 World Anti-Doping Agency Prohibited List under S2 (growth hormone fragments), prohibited at all times [9].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed AOD-9604?
AOD-9604 was developed by a biochemistry group at Monash University in Australia, with F.M. Ng as lead author of the first paper in 2000. Metabolic Pharmaceuticals, founded in 1998, ran its clinical development.
Is AOD-9604 FDA approved?
No. As of 22 Oct 2026 AOD-9604 is not FDA-approved, and an FDA advisory committee voted 12–0 in December 2024 against adding it to the 503A compounding bulks list.
What is AOD-9604 derived from?
It is a synthetic copy of amino acids 177 to 191 of human growth hormone with one added tyrosine, for 16 residues in total.
What happened to AOD-9604's clinical program?
After a 536-person trial did not meet its objectives, Metabolic Pharmaceuticals announced in February 2007 that it would not continue AOD-9604 as an obesity drug.
Is AOD-9604 on the WADA prohibited list?
Yes. It is named on the 2026 WADA Prohibited List under S2 growth hormone fragments, prohibited at all times.
Sources
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274–278. Link
- Biotech Daily. CEO interview: Metabolic Pharmaceuticals, Roland Scollay (undated). Link
- US FDA, CDER. Evaluation of AOD-9604-related bulk drug substances for inclusion on the 503A Bulks List (briefing document). 5 Nov 2024. Link
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7–15. Link
- BioWorld. Metabolic jumps, slides on trial data, analyst criticism. 22 Dec 2004. Link
- US FDA. Pharmacy Compounding Advisory Committee, 4 Dec 2024: final summary minutes. Approved 21 Feb 2025. Link
- US FDA. Safety risks associated with certain bulk drug substances nominated for use in compounding. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List (in force 1 Jan 2026): S2.2.3. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
